← Eichor
Study identifier: NCT05472818 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

SV2A Density Cannabis Use Disorder

Condition: Cannabis Use Disorder · Healthy  ·  Sponsor: Yale University

PhaseEARLY_Phase 1
Planned participants51
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersYes

About this study

The main purpose of this study is to determine whether hippocampal synaptic vesicle density estimated by hippocampal \[11C\]APP-311/\[11C\]UCB-J binding in individuals diagnosed with cannabis use disorder (CUDs) improves with at least 4 weeks of confirmed abstinence from cannabis, in comparison to healthy controls (HCs). Furthermore, any change in synaptic vesicle density will be placed in functional context by measuring verbal memory, which is sensitive to hippocampal function, before and after at least 4 weeks of confirmed abstinence. Finally, the relationship between hippocampal \[11C\]UCB-J binding in CUDs with measures of cannabis exposure (e.g., age of initiation, cumulative lifetime dose) will be explored.

This description comes directly from the study's public registry record.

Talk to the study team

Shannon Zeilman  ·  203-974-7822  ·  shannon.zeilman@yale.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Yale University School of MedicineNew Haven, Connecticut, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05472818